Compare APPN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | SUPN |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2017 | 2010 |
| Metric | APPN | SUPN |
|---|---|---|
| Price | $37.92 | $41.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $29.80 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 846.3K | 531.5K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $226,743,000.00 | ★ $392,755,000.00 |
| Revenue This Year | $13.79 | $22.70 |
| Revenue Next Year | $10.56 | $19.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.29 | N/A |
| 52 Week Low | $18.63 | $41.11 |
| 52 Week High | $46.06 | $59.68 |
| Indicator | APPN | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 30.39 |
| Support Level | $35.88 | N/A |
| Resistance Level | $43.92 | $52.33 |
| Average True Range (ATR) | 2.09 | 1.22 |
| MACD | -0.92 | -0.32 |
| Stochastic Oscillator | 46.66 | 8.01 |
Appian Corp is an enterprise software company whose platform unifies process orchestration, artificial intelligence, and data for automating complex business operations. Its platform combines low-code application development, process automation and process mining, AI agents, and a data fabric that connects information across an organization's existing systems without replicating it. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based, with the remainder coming from services, and much of that subscription revenue comes from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations and also has a presence internationally.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.